RGBPP.PFD (Regen BioPharma) OCF Margin %: -106.78% (As of Mar. 2026)


What is Regen BioPharma OCF Margin %?

Regen BioPharma RGBPP.PFD -19.35% OCF Margin % is -106.78% as of Mar. 2026. The stock has 7 warning signs investors should review. Among 955 Biotechnology companies, Regen BioPharma ranks worse than 61.47% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Regen BioPharma's Cash Flow from Operations for the three months ended in Mar. 2026 was $-0.06 Mil. Regen BioPharma's Revenue for the three months ended in Mar. 2026 was $0.06 Mil. Therefore, Regen BioPharma's OCF Margin % for the quarter that ended in Mar. 2026 was -106.78%.

As of today, Regen BioPharma's current OCF Yield % is -467.65%.

The historical rank and industry rank for Regen BioPharma's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Regen BioPharma was 17.27%. The lowest was -1721.82%. And the median was -377.74%.

RGBPP.PFD's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Regen BioPharma OCF Margin % Related Terms

Regen BioPharma OCF Margin % Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma OCF Margin % Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -661.40 -257.20 -73.42 -317.30 -162.03

Regen BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -171.19 -94.92 -271.19 -335.59 -106.78

Regen BioPharma OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Regen BioPharma's OCF Margin for the fiscal year that ended in Sep. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-0.384/0.237
=-162.03 %

Regen BioPharma's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.063/0.059
=-106.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -106.78% mean?
Regen BioPharma (RGBPP.PFD) has a OCF Margin % of -106.78% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #587 out of 955 companies in the Biotechnology industry, placing it in the top 61.5%.
Is Regen BioPharma's OCF Margin % too high?
Regen BioPharma's current OCF Margin % is -106.78%. Based on the distribution chart, Regen BioPharma ranks #587 out of 955 companies in the Biotechnology industry, which is below the industry midpoint.
How does Regen BioPharma's OCF Margin % compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #587 out of 955 companies for OCF Margin %. This places Regen BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current OCF Margin % is -106.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Regen BioPharma (RGBPP.PFD) has a current OCF Margin % of -106.78%. The current OCF Margin % is -106.78%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Regen BioPharma (RGBPP.PFD), the current OCF Margin % is -106.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBP:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.